Le Lézard
Classified in: Health
Subject: TRI

CSSi's MyClinicalTrial ID Database Exceeds 1 Million Patients


GLEN BURNIE, Md., July 18, 2018 /PRNewswire/ -- CSSi, a global full-service patient recruitment company, today announced that its MyClinicalTrial ID (MCT ID) database has expanded to over one million patients. MCT ID was developed to improve the investigator site selection and patient recruitment processes in a confidential and HIPAA-compliant manner. This increases study success by guaranteeing that only sites with patients who meet the study criteria will be selected to participate as investigative sites.

Historically, the process of site selection has been extremely inefficient because there has not been any way to validate the sites' patient population against the study's inclusion/exclusion criteria. CSSi's MCT ID platform queries the site's de-identified patient records to ensure the site has the most eligible patients, specific for each study. Once the study is open for enrollment, the site can contact this list of patients who meet the study criteria in the first weeks of the study, which results in enrolling three to five times more patients in a more rapid timeframe.  

"This data-driven approach is helping to change the landscape of finding and enrolling patients for clinical trials in a more efficient way," said Chris Trizna, President, CSSi. "MCT ID has enabled our clients to select more qualified sites and enroll their studies faster."

CSSi's MCT ID is a worthy solution for avoiding study startup and enrollment delays. For more information about CSSi and MCT ID, visit www.cssienroll.com/technology.html.

About CSSi:
CSSi delivers global patient recruitment solutions to sponsors, CROs and investigative sites that ensure successful enrollment for clinical trials - on time, every time. CSSi brings years of patient recruitment and retention knowledge across all disciplines: recruitment planning and budgeting, media advertising, website and creative development, project management, marketing and consulting, and technology solutions. For more information, please visit www.cssienroll.com, email [email protected], or call (866) 277-4888.

Follow Us!
Facebook.com/CSSiEnroll ? Twitter.com/EnrollPatients ? LinkedIn.com/Company/Clinical-Site-Services

Media Contact:
Courtney Megaughey
CSSi
(443) 308-5831
[email protected]

SOURCE CSSi


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: